Drug Profile
Research programme: boronated bispecific antibodies - Immunomedics
Alternative Names: Boronated bispecific antibodies research programme - ImmunomedicsLatest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator Immunomedics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 02 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 12 Jun 2001 New profile